Lexaria Bioscience: Oral Drug Delivery Technology Targets Next-Gen Weight Loss Market [Globe and Mail, The (Toronto, Canada)]
Lexaria Bioscience Corp. (LEXX)
Company Research
Source: Globe and Mail, The
Lexaria Bioscience is developing a patented oral drug delivery technology designed to improve absorption and reduce adverse effects in next-generation weight loss drugs. In a recent clinical study, the technology reduced adverse events by up to 50%, positioning the company within a rapidly expanding multibillion-dollar pharmaceutical market. The pharmaceutical industry is racing to improve oral metabolic and weight-loss treatments. While new therapies have demonstrated strong effectiveness, tolerability and side-effects remain major adoption barriers. Lexaria Bioscience is approaching the problem differently - by improving how drugs enter the body rather than changing the active ingredient itself. In a recent clinical study, the company's patented oral delivery platform reduced adverse events by up to 50%. That result highlights a key industry challenge: absorption efficiency. Many oral medications are limited not by the molecule's effectiveness but by how the body processe
Show less
Read more
Impact Snapshot
Event Time:
LEXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LEXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LEXX alerts
High impacting Lexaria Bioscience Corp. news events
Weekly update
A roundup of the hottest topics
LEXX
News
- Lexaria Bioscience: Improving Oral Weight-Loss Drug Tolerability [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke PointGlobeNewswire
- Lexaria releases additional results from Phase 1b study GLP-1-H24-4 [Yahoo! Finance]Yahoo! Finance
- Lexaria Bioscience (NASDAQ:LEXX) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
LEXX
Analyst Actions
- 12/26/25 - HC Wainwright
LEXX
Sec Filings
- 2/6/26 - Form 8-K
- 1/28/26 - Form 8-K
- 1/28/26 - Form S-8
- LEXX's page on the SEC website